Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Novartis Pharma (encorafenib (LGX818))

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A key protein kinase in the RAS/RAF/MEK/ERK signaling pathway. It regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Business Products and Services
Acquirer
Primary Office
  • Boulder, CO
  • United States

Novartis Pharma (encorafenib (LGX818)) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Novartis Pharma (encorafenib (LGX818))‘s full profile, request access.

Request full access to PitchBook

Novartis Pharma (encorafenib (LGX818)) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Novartis Pharma (encorafenib (LGX818))‘s full profile, request access.

Request full access to PitchBook